Monte Rosa Therapeutics (NASDAQ: GLUE - Get Free Report) and ImmunityBio (NASDAQ: IBRX - Get Free Re

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

U.S. stocks rose Friday; Humana jumped 12.3% after improved 2027 Medicare Advantage ratings and reaf

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage immunotherapy company, today annou

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has earned an average rating of "Moderate Buy" fr

ImmunityBio Inc. (NASDAQ:IBRX) shares are soaring Friday, extending a steadily rising pattern that's

ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that&

State Street Corp raised its position in ImmunityBio, Inc. (NASDAQ: IBRX) by 20.8% in the second qua

ImmunityBio (IBRX) was a big mover last session on higher-than-average trading volume. The latest tr

Tidal Investments LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ: IBRX) in the und

ImmunityBio, Inc. (NASDAQ: IBRX - Get Free Report) has been given a consensus rating of "Moderate Bu

ImmunityBio (IBRX) reported earnings 30 days ago. What's next for the stock?

ImmunityBio is rated a strong buy, driven by ANKTIVA's FDA approval for BCG-unresponsive NMIBC and s

Canada Pension Plan Investment Board acquired a new position in shares of ImmunityBio, Inc. (NASDAQ:

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead Class Action Law

Did you buy CAPR securities between December 17, 2025 and July 26, 2026? Affected CAPR Investor Summ

Bell and Brown Wealth Advisors LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ: IBRX) in the

Bank of America Corp DE grew its stake in shares of ImmunityBio, Inc. (NASDAQ: IBRX) by 2.7% in the

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunothe

ImmunityBio beat Q2 earnings and revenue estimates as record Anktiva sales and continued adoption fu

ImmunityBio (IBRX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Esti

ImmunityBio, Inc. ([url="]NASDAQ: IBRX[/url]), a commercial-stage biotechnology company, today annou

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which beat the analyst cons

ImmunityBio secures UAE marketing authorization for ANKTIVA across two cancer indications, expanding

The UAE authorization further expands ANKTIVA’s global regulatory footprint to 34 countries. The BCG

Lucid, Figma, SoundHound and Ondas are among the most heavily shorted stocks in the market right now

Jim Cramer recommended buying CAVA Group (CAVA), citing its potential and tasty, clean, and fun conc

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

ImmunityBio, Inc. ((

ImmunityBio, Inc. ((IBRX), a commercial-stage immunotherapy company, today announced preliminary res

The findings were presented at the International Society for Pharmacoeconomics and Outcomes Research

TAT Technologies Ltd (TATT) reported better-than-expected Q1 results, sending shares up 11.7%. Other

ImmunityBio shares rise after the FDA accepted ANKTIVA's sBLA for NMIBC, with Phase 2/3 data sho

HC Wainwright & Co. analyst Andres Y. Maldonado reiterates ImmunityBio (NASDAQ:IBRX) with a B

Supplemental BLA seeks to expand the ANKTIVA label to include patients with BCG-unresponsive NMIBC w

ImmunityBio reported AUA 2026 data showing ANKTIVA plus BCG outperformed rival therapies in key blad

NAI+BCG versus Nadofaragene Results:NAI+BCG treated patients were twice as likely to achieve a compl

ImmunityBio secures exclusive U.S. rights to Japan BCG Lab's Tokyo strain of BCG, aiming to end

Five issued U.S. patents cover the combination of ImmunityBio's IL-15 receptor agonist (NAI) wit

Positive Phase III readout of National Cancer Institute-sponsored SWOG S1602 randomized clinical tri

ImmunityBio shares fall after Q1 losses misses estimates despite strong ANKTIVA sales growth and upd

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.08) per share which missed the analyst co

ImmunityBio (NASDAQ:IBRX) reported quarterly losses of $(0.62) per share which missed the analyst co

ImmunityBio (IBRX) stock is surging. Read why Patrick Soon-Shiong's manufacturing updates and ne

Cross-trial analyses comparing ANKTIVA + BCG with nadofaragene firadenovec-vncg and TAR-200 provide

The Avis Budget short squeeze appears to be spreading to other stocks like Beyond Meat, Opendoor and

ImmunityBio Inc. (NASDAQ:IBRX) shares are trading higher Tuesday after it launched ANKTIVA in Saudi

ImmunityBio stock rises as Q1 revenue jumps 168% and Anktiva adoption grows, even as FDA warning pro